Abstract
Introduction: One of the most significant challenges in modern medicine is the increasing resistance of microorganisms. Very few new drugs are being registered, and those that are currently available are becoming less and less effective. Cefiderocol is one of the few novel antibiotics that were registered in the last decade.
Materials and methods: Two independent researchers searched PubMed for articles using the keyword “cefiderocol”; 700 results were found, and 13 articles fulfilled the inclusion and exclusion criteria.
Results: The non-inferiority of cefiderocol compared to carbapenems was demonstrated in several different studies. Comparative and descriptive statistics suggest that its safety might also be comparable. Antibiotic resistance to cefiderocol remains at a low level; however, some bacteria have developed an unknown mechanism of resistance to it. No interactions between cefiderocol and other drugs, no impact on the QT/QTc interval, and no influence of body iron levels on cefiderocol have been found so far.
Conclusion: Further studies are needed to assess its effectiveness and side effects in different clinical conditions; however, it appears to be a promising option for patients with limited treatment options.